Cargando…

A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration

Current SARS-CoV-2 Omicron subvariants impose a heavy burden on global health systems by evading immunity from most developed neutralizing antibodies and vaccines. Here, we identified a nanobody (aSA3) that strongly cross-reacts with the receptor binding domain (RBD) of both SARS-CoV-1 and wild-type...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Huan, Zhang, Xinghai, Zeng, Weihong, Zhou, Junhui, Chi, Xiangyang, Chen, Shaohong, Zheng, Peiyi, Wang, Meihua, Wu, Yan, Zhao, Dan, Gong, Fanwu, Lin, Haofeng, Sun, Hancong, Yu, Changming, Shi, Zhengli, Hu, Xiaowen, Zhang, Huajun, Jin, Tengchuan, Chiu, Sandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734137/ https://www.ncbi.nlm.nih.gov/pubmed/36494344 http://dx.doi.org/10.1038/s41421-022-00497-w

Ejemplares similares

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
por: Ma, Huan, et al.
Publicado: (2022)

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
por: Zhang, Xinghai, et al.
Publicado: (2022)

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
por: Wu, Xilin, et al.
Publicado: (2021)

Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins
por: Misson Mindrebo, Laetitia, et al.
Publicado: (2023)

Design of nanobody-based bispecific constructs by in silico affinity maturation and umbrella sampling simulations
por: Bai, Zixuan, et al.
Publicado: (2022)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
por: Hao, Shuai, et al.
Publicado: (2022)

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
por: Xia, Baijin, et al.
Publicado: (2023)

Nanobodies Provide Insight into the Molecular Mechanisms of the Complement Cascade and Offer New Therapeutic Strategies
por: Zarantonello, Alessandra, et al.
Publicado: (2021)

A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
por: Hanke, Leo, et al.
Publicado: (2022)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
por: Ma, Linlin, et al.
Publicado: (2022)

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
por: Yang, Xiao-mei, et al.
Publicado: (2023)

Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants
por: Sun, Hancong, et al.
Publicado: (2022)

Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates
por: Wu, Yi, et al.
Publicado: (2022)

Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism
por: Mayer, Annalina V., et al.
Publicado: (2021)

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
por: Hambach, Julia, et al.
Publicado: (2022)

Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
por: Ma, Huan, et al.
Publicado: (2021)

Delivery of an anti‐transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons
por: Gomes, João R., et al.
Publicado: (2018)

Research Progresses and Applications of Fluorescent Protein Antibodies: A Review Focusing on Nanobodies
por: Chen, Yu-Lei, et al.
Publicado: (2023)

Recombinant expression of nanobodies and nanobody-derived immunoreagents
por: de Marco, Ario
Publicado: (2020)

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization
por: Yang, Jing, et al.
Publicado: (2023)

Increased pathogenicity and aerosol transmission for one SARS-CoV-2 B.1.617.2 Delta variant over the wild-type strain in hamsters
por: Zhang, Xinghai, et al.
Publicado: (2022)

Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies
por: Yang, Fa, et al.
Publicado: (2016)

Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling
por: Gesiorowski, Annika, et al.
Publicado: (2023)

Harringtonine: A more effective antagonist for Omicron variant
por: Hu, Shiling, et al.
Publicado: (2023)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
por: Bannas, Peter, et al.
Publicado: (2017)

Enhancement of extracellular bispecific anti‐MUC1 nanobody expression in E. coli BL21 (DE3) by optimization of temperature and carbon sources through an autoinduction condition
por: Rezaei, Leila, et al.
Publicado: (2020)

Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants
por: Chi, Xiangyang, et al.
Publicado: (2023)

Nanobodies that Neutralize HIV
por: Weiss, Robin A., et al.
Publicado: (2019)

The Therapeutic Potential of Nanobodies
por: Jovčevska, Ivana, et al.
Publicado: (2019)

Special Issue: Nanobody
por: Chames, Patrick, et al.
Publicado: (2020)

Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY(®) compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation
por: Kyuuma, Masanao, et al.
Publicado: (2023)

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22)
por: Wu, Xilin, et al.
Publicado: (2022)

Development of a Nanobody-based lateral flow assay to detect active Trypanosoma congolense infections
por: Pinto Torres, Joar E., et al.
Publicado: (2018)

Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine–Nanobody Complex
por: Desmyter, Aline, et al.
Publicado: (2017)

Selecting Nanobodies Specific for the Epidermal Growth Factor from a Synthetic Nanobody Library
por: Serrano-Rivero, Yunier, et al.
Publicado: (2023)

Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination
por: Chi, Xiangyang, et al.
Publicado: (2022)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fbd1cl6jj754crvb6pbn20eu4t